Please use this identifier to cite or link to this item: https://ir.swu.ac.th/jspui/handle/123456789/13494
Full metadata record
DC FieldValueLanguage
dc.contributor.authorYodying H.
dc.contributor.authorMatsuda A.
dc.contributor.authorMiyashita M.
dc.contributor.authorMatsumoto S.
dc.contributor.authorSakurazawa N.
dc.contributor.authorYamada M.
dc.contributor.authorUchida E.
dc.date.accessioned2021-04-05T03:24:17Z-
dc.date.available2021-04-05T03:24:17Z-
dc.date.issued2016
dc.identifier.issn10689265
dc.identifier.other2-s2.0-84958177341
dc.identifier.urihttps://ir.swu.ac.th/jspui/handle/123456789/13494-
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84958177341&doi=10.1245%2fs10434-015-4869-5&partnerID=40&md5=2b180735aba023c4552a9ea50d20eccc
dc.description.abstractBackground: Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have been reported to predict oncologic outcomes in patients with various types of cancer. However, their prognostic value in patients with esophageal cancer is unclear. In this meta-analysis, we evaluated the prognostic significance of NLR and PLR in esophageal cancer patients. Methods: We performed comprehensive searches of electronic databases to identify studies that evaluated the prognostic impact of pretreatment NLR and PLR in esophageal cancer patients. The end points were overall survival (OS), disease-free survival, and clinicopathologic parameters. A meta-analysis using random-effects models was performed to calculate hazard ratios (HRs) or odds ratios with 95 % confidence intervals (CIs). Results: Seven retrospective, observational, cohort studies involving 1540 patients were included. All seven studies evaluated NLR, and four evaluated PLR. Both high NLR (HR 1.40, 95 % CI 1.08–1.81, P = 0.01) and high PLR (HR 1.59, 95 % CI 1.14–2.21, P = 0.006) were significantly predictive of poorer OS. NLR was not a significant predictor of disease-free survival. High PLR (HR 1.85, 95 % CI 1.50–2.28, P < 0.00001) but not NLR was significantly predictive of poorer OS in a subgroup of patients who underwent curative surgery without neoadjuvant chemoradiation. Both high NLR and high PLR were significantly associated with deeper tumor invasion and lymph node metastasis. Conclusions: NLR and PLR are associated with tumor progression and are predictive of poorer survival in patients with esophageal cancer. These ratios may thus help to inform treatment decisions and predict treatment outcomes. © 2015, Society of Surgical Oncology.
dc.subjectArticle
dc.subjectcancer patient
dc.subjectcancer prognosis
dc.subjectcancer surgery
dc.subjectchemoradiotherapy
dc.subjectcohort analysis
dc.subjectdata base
dc.subjectdisease free survival
dc.subjectesophagus cancer
dc.subjectesophagus surgery
dc.subjecthuman
dc.subjectlymph node metastasis
dc.subjectmeta analysis
dc.subjectneutrophil lymphocyte ratio
dc.subjectobservational study
dc.subjectoutcome assessment
dc.subjectoverall survival
dc.subjectplatelet lymphocyte ratio
dc.subjectpredictive value
dc.subjectretrospective study
dc.subjectsystematic review
dc.subjecttumor invasion
dc.subjectcancer staging
dc.subjectEsophageal Neoplasms
dc.subjectlymphocyte
dc.subjectmultimodality cancer therapy
dc.subjectneutrophil
dc.subjectpathology
dc.subjectprognosis
dc.subjectsurvival rate
dc.subjectthrombocyte
dc.subjectBlood Platelets
dc.subjectCombined Modality Therapy
dc.subjectEsophageal Neoplasms
dc.subjectHumans
dc.subjectLymphocytes
dc.subjectNeoplasm Staging
dc.subjectNeutrophils
dc.subjectPrognosis
dc.subjectSurvival Rate
dc.titlePrognostic Significance of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Oncologic Outcomes of Esophageal Cancer: A Systematic Review and Meta-analysis
dc.typeArticle
dc.rights.holderScopus
dc.identifier.bibliograpycitationAnnals of Surgical Oncology. Vol 23, No.2 (2016), p.646-654
dc.identifier.doi10.1245/s10434-015-4869-5
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.